Skip to contentpdufa.bio

rexlemestrocel-L expanded

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

rexlemestrocel-L expanded is a Mesoblast Ltd program in chronic inflammatory low back pain due to degenerative disc disease. Its next catalyst is a Readout in Q4 2027.

MESO catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: chronic inflammatory low back pain due to degenerative disc disease. Sponsor: Mesoblast Ltd (MESO). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027MESO

Questions

When is rexlemestrocel-L expanded's next FDA decision or readout?

The next tracked catalyst for rexlemestrocel-L expanded is a Readout in Q4 2027.

What happened at rexlemestrocel-L expanded's most recent FDA decision?

No FDA decision for rexlemestrocel-L expanded is in our archive yet.

What is rexlemestrocel-L expanded used for?

In our records rexlemestrocel-L expanded is under review or in development for chronic inflammatory low back pain due to degenerative disc disease.

Who makes rexlemestrocel-L expanded?

Mesoblast Ltd (MESO).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.